Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19)
Compared with vaccines, antivirals for curbing COVID-19 (SARS-CoV-2 infection) have been developed at a much lower pace. Favipiravir has proven efficacious (in hamsters) but only at a very high dose which may not be feasible in humans. Remdesivir is the sole antiviral approved by the US FDA, but it...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
CSIRO Publishing
2021-01-01
|
| Series: | Microbiology Australia |
| Online Access: | https://www.publish.csiro.au/ma/pdf/MA21013 |